Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Tecentriq eroding Opdivo market share

Roche’s cancer drug Tecentriq hit the market months behind immuno-oncology (I/O) medicines from Merck and Bristol-Myers Squibb, but is making up lost ground.

Read More »

FDA Lashes Out at Jazz Pharma CMO for Continued Regulatory Violations

The U.S. Food and Drug Administration issued a warning letter to U.K.-based Porton Biopharma for continued regulatory violations in the manufacturing process, particularly a leukemia drug made for Jazz Pharmaceuticals.

Read More »

Sanders Courses and Holds Courses

This is an instructional guide to assist those who wish to learn to write a composition that is effective, or for those of you wanting a refresher on successful writing. After scanning this post you need to have a basic knowledge of the important thing rules of writing a highly effective dissertation. Writing an effective […]

Read More »

Barr Labs settles Cipro antitrust case

Barr reached a $225 million settlement in an antitrust class action accusing the drugmaker of keeping a generic version of Bayer’s antibiotic Cipro off the market.

Read More »

How-to Stack to Get A Check Part 2

Stanford University also has a specialized class within this discipline, called Developing Mobile Apps with Web Systems. He creates java-based net and/or intranet interfaces according to consumers’ specifications. Along side every one of these systems, he additionally utilizes additional languages and instruments for programming, compiling, and doing applications. He’s additionally liable to build up sport […]

Read More »

How to Produce An Individual Response Article

Researching the newest from has which may become a tiny concern. The issue being that they’re nearly the dimension they state to be to the draw, particularly when compared to the Flex Ballroom Trousers analyzed back December. Once they first appeared, and that I attempted to slip them on, everything healthy pretty much aside from […]

Read More »

Lundbeck bets on shark antibodies for new brain drugs

Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer’s and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix.

Read More »

Create better, publish more and practice writing

Google gets application developer Bitspin A software creator, Bitspin responsible for the alarm clock software Appropriate have been purchased by Google. Within an news on Bitspin’s website. The Zurich -based firm said: “We’re delighted to broadcast that Bitspin is joining Google, where we’ll proceed to complete what we enjoy: building wonderful items which can be […]

Read More »

Summary Template

Signing up for college can be a skillfully valuable and privately experience, and, consider it or attending your lessons tremendously attributes to the experience. It may look tempting to keep reaching that sleep alarm, however, you spend a cost for skipping your class. On what you make of it, your faculty schooling mainly depends. School […]

Read More »

U.S. court issues injunction on assistance for dialysis patients

A U.S. court has issued a preliminary injunction on a new federal rule that dialysis providers have said would prevent patients from using charitable assistance to buy private health insurance, Fresenius Medical Care (FMC) said.

Read More »

Cancer, hepatitis treatments set for boost as China overhauls drugs list

China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and hemophilia.

Read More »

J&J to acquire Actelion for $30 billion

Johnson & Johnson will launch an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion for $280 per share.

Read More »

Health insurers quietly shape Obamacare replacement with fewer risks

U.S. health insurers are making their case to Republican lawmakers over how Americans sign up for individual insurance and pushing for other changes to shape the replacement of former President Barack Obama’s national healthcare law.

Read More »

Sleep apnea screenings lack evidence: U.S. panel

It’s unclear whether everyone should be screened for a common sleep-related breathing problem, a government-backed U.S. panel says.

Read More »

Possible liver injury added to Biogen MS drug label

The prescribing label for Biogen’s big-selling oral multiple sclerosis drug Tecfidera has been updated to include a warning of potential liver injury.

Read More »

WHO seeks new leader to rebuild damaged reputation

The list of candidates to lead the World Health Organization (WHO) and rebuild its battered reputation after its slow response to West Africa’s deadly Ebola outbreak was whittled down to three, with a final choice due in May 2017.

Read More »

Study Proves Climate Impacts on Weight Loss

A new study published in Scientific Reports found Noom Coach users who lived in colder temperatures were most successful at losing weight.

Read More »

Healthcare Leaders To Congress, Administration: Improve Value-Based Care Movement

In a letter to Congress and the Administration, leading healthcare organizations called for a renewed effort to move to value-based, patient-centered payment models that reward improved quality and cost-effective care. Central to this effort is addressing the perverse incentives in the fee-for-service system, and antiquated laws and regulations that impede innovation and care coordination.

Read More »

Aurobindo Receives FDA Approval for Dalfampridine Extended-Release Tablets, 10 mg

The U.S. FDA granted final approval to Aurobindo Pharma Limited’s generic treatment for multiple sclerosis.

Read More »

Now Open for Enrollment: 2017 Healthcare Businesswomen’s Association (HBA) NY/NJ Group Mentoring Program

Registration for the 2017 HBA New York/New Jersey area Group Mentoring Program is open now through 2/28/17.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom